Earlier Data, More Support: EMA Explains Priority Medicines Plan
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has confirmed that its proposed priority medicines initiative, PRIME, will be aimed at identifying at a much earlier stage new medicines that fulfil the current criteria for accelerated assessment – that is, those that could benefit patients who have no treatment options or that represent a major therapeutic advantage over existing products.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports